Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
    Research/Science 5/11/2023

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 KX-826 (topical) 0.5% 2x daily 24 weeks
    💧 Minoxidil (topical)
    💧 RU58841 (topical) 5% 1x daily 6 months
    💊 Dutasteride (oral)
    💊 oral Minoxidil (oral)
    the tone is 😐 neutral with some growth results.

    Other terms

    Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
    View this post in the Community →

    Similar Community Posts Join

    5 / 423 results

      community Received Kintor’s KX-826 Today

      in Product  84 upvotes 1 year ago
      A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

      community Clascoterone - what we have right now

      in Research/Science  18 upvotes 3 weeks ago
      Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

      community KX-826 Pyrilutamide1% coming soon

      in Update  152 upvotes 1 year ago
      KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

    Related Research

    6 / 173 results